ERA PerMed

Basic Information

Description

ERA PerMed will serve as a funding vehicle of topics identified in the Strategic Research and Innovation Agenda
(SRIA) in Personalised Medicine and the Action Plan of ICPerMed.
ERA PerMed will coordinate R&I efforts of the participating partners (funding agencies from EU, associate countries
to H2020 and third countries). The main objective is planning, implementing, monitoring and disseminate up to
four joint transnational calls (JTCs) tackling the value change in full to fund multidisciplinary transnational research
projects covering each at least three slots of the value chain regarding Personalised Medicine.
The ERA PerMed consortium is open to enlargement for the planned JTCs. According to funding scheme’s rules,
ERA PerMed partners commit themselves to implement one call with top-up co-funding from the EC, and include
funded project monitoring. Additionally, up to three non-cofunded calls will be carried, in order to broaden the scope
of action of the efforts made by the EC and funding organizations to foster the Personalised Medicine Research
Community and to be able to take into account recent changes within the landscape of personalised medicine, e.g. new
developments of emerging technologies and societal challenges, which reinforces and amplifies the expected impact
of ERA PerMed funding activity.
Cooperation and links with ICPerMed and a dialogue with patient organisations, other European stakeholders and
initiatives are crucial for both R&I and the implementation of their results and sustainability, which reinforces and
amplifies the expected impact of ERA PerMed funding activity.

H2020 Societal Challenges

H2020-SC1 (Health, demographic change and wellbeing)